LGND
Ligand Pharmaceuticals Inc.
stock NASDAQ

The integration is live. ColoAlert is now inside DoctorBox, a preventive platform with 1,000,000+ users and 10M+ results. That means a real at-home funnel in Germany, a market that sees about 60,000 new CRC cases a year. The next 30 to 90 days should be about numbers, not noise. Start a simple weekly countdown: app-to-order conversion, completed kits per month, median turnaround time, and first reorder clusters. Pooled next-gen performance gives this teeth: CRC sensitivity \~92 percent, advanced adenomas \~82 percent, high-grade dysplasia \~95.8 percent. Orders route to European Oncology Lab, a long-term partner, so quality control stays tight.
For readers who want a broader watchlist, Halozyme (HALO) shows how platforms convert into recurring revenue as partners adopt Enhanze, and Ligand (LGND) demonstrates how royalty engines smooth quarters as programs scale.
If МYNZ posts real conversion and completion data, the market can underwrite volume before any U.S. readout in 2025.

The integration is live. ColoAlert is now inside DoctorBox, a preventive platform with 1,000,000+ users and 10M+ results. That means a real at-home funnel in Germany, a market that sees about 60,000 new CRC cases a year. The next 30 to 90 days should be about numbers, not noise. Start a simple weekly countdown: app-to-order conversion, completed kits per month, median turnaround time, and first reorder clusters. Pooled next-gen performance gives this teeth: CRC sensitivity \~92 percent, advanced adenomas \~82 percent, high-grade dysplasia \~95.8 percent. Orders route to European Oncology Lab, a long-term partner, so quality control stays tight.
For readers who want a broader watchlist, Halozyme (HALO) shows how platforms convert into recurring revenue as partners adopt Enhanze, and Ligand (LGND) demonstrates how royalty engines smooth quarters as programs scale.
If МYNZ posts real conversion and completion data, the market can underwrite volume before any U.S. readout in 2025.